A systematic review and network meta-analysis of the efficacy and safety of third-line and over third-line therapy after imatinib and TKI resistance in advanced gastrointestinal stromal tumor

被引:2
|
作者
Xiao, Xianhao [1 ]
Yuan, Weiye [1 ]
Wang, Chong [1 ]
Song, He [1 ]
机构
[1] First Hosp China Med Univ, Shenyang, Liaoning, Peoples R China
关键词
gastrointestinal stromal tumor; precise targeted therapy; refractory GIST; network meta-analysis; systematic review; PHASE-III; KINASE INHIBITOR; TYROSINE KINASE; SUPPORTIVE CARE; OPEN-LABEL; MULTICENTER; SUNITINIB; KIT; MESYLATE; TRIAL;
D O I
10.3389/fphar.2022.978885
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tyrosine kinase inhibitors (TKIs) have greatly improved the prognosis of unresectable and metastatic gastrointestinal stromal tumors (GISTs) in the last two decades. Imatinib and sunitinib are recommended as first-line and second-line therapies, respectively. However, there is a lack of precision therapy for refractory GISTs regarding therapy after imatinib and sunitinib. We comprehensively searched electronic databases, including PubMed, EMBASE, Web of Science, Cochrane Library, and ClinicalTrials, from inception to October 2022. Randomized controlled trials featuring comparisons with third-line or over third-line therapies against GISTs were eligible. The primary outcome was progression-free survival (PFS). All network calculations were performed using random effect models, and the ranking of regimens were numerically based on the surface under the cumulative ranking (SUCRA) statistics. A total of seven studies were eligible for inclusion in this network meta-analysis. After analysis, ripretinib was ranked at the top in progression-free survival (PFS), overall survival (OS), and disease control rate (DCR) (SUCRA statistics: 83.1%, 82.5%, and 86.5%, respectively), whereas nilotinib and pimitespib presented better tolerability (SUCRA statistics: 64.9% and 63.8%, respectively). We found that regorafenib seemed more reliable for clinical administration, and ripretinib showed good effectiveness for the over third-line therapy. Precise targeted therapy is a critical direction for the future treatment of GIST, and more high-quality studies of new agents are expected.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Lu-PSMA-617 in combination with third-line therapy for castration-resistant prostate cancer: A systemic review and meta-analysis
    Akbar, Usman Ali
    Ali, Fatima
    Vikash, Sindhu
    Khalid, Saad
    Farooqui, Sabeeh
    Aman, Aleena
    Qazi, Shaheryar
    Qadeer, Muhibullah Abdul
    Rehman, Mohammad Ebad Ur
    Zubair, Rameesha
    Ashraf, Muhammad Aizaz
    Shabbir, Muhammad Asad
    Ahmed, Muhammad Ihsan
    Khalid, Alina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] The efficacy and safety of amrubicin in non-small-cell lung cancer patients beyond third-line therapy
    Saigusa, M.
    Sakurai, S.
    Akamatsu, T.
    Yamamoto, A.
    Shishido, Y.
    Akita, T.
    Morita, S.
    Asada, K.
    Shirai, T.
    Eto, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S137 - S137
  • [43] Efficacy and Safety of Amrubicin in Non-Small-Cell Lung Cancer Patients Beyond Third-Line Therapy
    Saigusa, Mika
    Asada, Kazuhiro
    Akamatsu, Taisuke
    Tanaka, Yuko
    Endo, Yoshinari
    Yamamoto, Akito
    Morita, Satoru
    Shirai, Toshihiro
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (1-2) : 52 - 56
  • [44] COST-EFFECTIVENESS ANALYSIS OF THIRD-LINE PAZOPANIB VERSUS REGORAFENIB FOR METASTATIC OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS IN CHINA
    Rui, M.
    Wang, Yc
    Cao, Yd
    Fei, Z.
    Li, Hc
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S56 - S56
  • [45] Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study
    Zhao, Jie
    Guo, Yongzhong
    Feng, Tianshuo
    Rong, Dawei
    Kong, Xiangyi
    Huang, Tian
    Lopez-Lopez, Victor
    Yarmohammadi, Hooman
    Sakamoto, Yoshihiro
    Zhu, Deming
    Yao, Aihua
    Xia, Yongxiang
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (06) : 2549 - 2558
  • [46] Third-Line Palliative Systemic Therapy for Advanced Biliary Tract Cancer: Multicentre Review of Patterns of Care and Outcomes
    Gray, Simon
    Letissier, Octave
    d'Abrigeon, Constance
    Shah, Dinakshi
    Wardell, Stephen
    Faluyi, Olusola
    Lamarca, Angela
    Hubner, Richard A.
    Edeline, Julien
    Valle, Juan W.
    McNamara, Mairead G.
    [J]. CANCERS, 2023, 15 (11)
  • [47] Efficacy of post-first-line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta-analysis
    Hu, Kehan
    Zhang, Hu
    Shu, Mingrong
    Wang, Xingyue
    [J]. CANCER MEDICINE, 2023, 12 (11): : 12187 - 12197
  • [48] Efficacy and safety of nivolumab and irinotecan as third-line chemotherapy for advanced gastric cancer: A multi-institutional retrospective study
    Kumanishi, Ryosuke
    Mitani, Seiichiro
    Kadowaki, Shigenori
    Matsushima, Tomohiro
    Takahashi, Naoki
    Ogata, Takatsugu
    Yasui, Hisateru
    Ogata, Misato
    Satake, Hironaga
    Narita, Yukiya
    Masuishi, Toshiki
    Bando, Hideaki
    Hara, Hiroki
    Muro, Kei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [49] Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis
    Zhang, Zhonghan
    Zhao, Yuanyuan
    Lu, Feiteng
    Hou, Xue
    Ma, Yuxiang
    Luo, Fan
    Zeng, Kangmei
    Zhao, Shen
    Zhang, Yaxiong
    Zhou, Ting
    Yang, Yunpeng
    Fang, Wenfeng
    Huang, Yan
    Zhang, Li
    Zhao, Hongyun
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (18)
  • [50] EFFICACY AND SAFETY OF VONOPRAZAN, SITAFLOXACIN AND AMOXICILLIN CONTAINING REGIMEN AS A THIRD-LINE HELICOBACTER PYLORI ERADICATION THERAPY: A MULTICENTER STUDY
    Masaoka, Tatsuhiro
    Mori, Hideki
    Suzuki, Hidekazu
    Mizuno, Tatsuto
    Yamamoto, Yuta
    Kameyama, Hisako
    Yamane, Tsuyoshi
    Imaeda, Hiroyuki
    Yoshioka, Masahiro
    Nakazawa, Atsushi
    Okazawa, Akira
    Kanai, Takanori
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S529 - S530